The arrival of generic semaglutide versions in India marks a significant shift in the diabetes treatment landscape. These generics, priced up to 80% lower than Novo Nordisk's Ozempic, offer a more affordable option for patients with Type II diabetes. However, this development raises important questions about patient safety and the role of healthcare providers. As the market opens up to more players, ensuring patient-selection criteria are met and providing adequate education on proper usage become crucial. The lower prices also mean that micro-dosing, while potentially beneficial, requires careful monitoring to prevent errors. This article delves into the implications of these generics, exploring the balance between accessibility and safety in healthcare.
